Click Here For COVID-19 (Coronavirus) Studies

RecruitMe Clinical Trial

A randomized, multicenter, double-blind, placebo-controlled, Phase 2b Study to Assess the Safety and Efficacy of IGV-001, an Autologous Cell Immunotherapy With Antisense Oligonucleotide Targeting IGF-1R, in Newly Diagnosed Patients With Glioblastoma Multiforme-the Immunesense Study
ImmuneSense Study: IGV-001 in Newly Diagnosed Patients With Glioblastoma
Sponsor:Imvax
Enrolling:Male and Female Patients
Age Range:Between 18 and 70 years old
IRB Number:AAAT5656
U.S. Government ID:NCT04485949
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information:

The purpose of this study is to see how safe the study medicine, IGV-001 plus standard of care (SOC), is and to compare IGV-001 with placebo to see if it works in slowing glioblastoma multiforme (GBM) tumor regrowth. SOC refers to the usual medicine(s) or procedures used to treat your cancer. A placebo looks like the study medicine but does not contain any medication (active ingredient). Researchers use a placebo to see if a study medicine works better or is safer than not taking anything at all.

Do You Qualify?
Are you 18 to 70 years old?YesNo
Have you been diagnosed with a brain tumor called glioblastoma multiforme (GBM)?YesNo
Submit
Cancel
You may be eligible for this study

Place Holder




Who Can I Contact?
For more information, please contact:
Research Nurse Navigator
Email: cancerclinicaltrials@cumc.columbia.edu
Phone: 212-342-5162